The projects and publications shown here provide some examples of the diverse range of projects facilitated by a genomics approach utilising the facilities and expertise in the University of Aberdeen Microarray service.

Publications

A selection of publications from projects utilising the facilities and expertise of the University of Aberdeen Microarray Service:

Mulder IE, Schmidt B, Lewis M, Delday M, Stokes CR, Bailey M, Aminov RI, Gill BP, Pluske JR, Mayer CD, Kelly D. Restricting microbial exposure in early life negates the immune benefits associated with gut colonization in environments of high microbial diversity. PLoS One. 2011; 6 (12): e28279. Epub 2011 Dec 22.

Collie-Duguid ESR, Sweeney K, Stewart KN, Miller ID, Smyth E and Heys SD. SerpinB3, a novel biomarker of neoadjuvant docetaxel benefit in breast cancer patients and a new prognostic tool. Breast Cancer Research and Treatment 2012; 132 (3):807-18. Epub 2011 Jun 22.

Bain G, Murray G, Denison A, Brooks M, Collie-Duguid E, McKiddie F, Gilbert F, El-Omar E, Park K, McAteer D, Phull P, Qadir A, Petty R. Aberdeen Microarray and PET in Optimising Oesophagogastric Cancer Response-1 (AMPETOOR-1). Preliminary Results: Annals of Oncology 2010; 21: 43.

Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C, Rochet V, Pisi A, De Paepe M, Brandi G, Eberl G, Snel J, Kelly D, Cerf-Benssusan. The key role of segmented filamentous bacteria in the co-ordinated maturation of gut helper T cell responses. Immunity 2009; 31: 677-689.

Fowler PA, Samantha Flannigan, Mathers A, Gillanders K, Lea RG, Wood MJ, Maheshwari A, Bhattacharya S, Collie-Duguid ESR, Baker PJ, Montiero A, O’Shaughnessy PJ. Gene expression analysis of human fetal ovarian primordial follicle formation. Journal of Clinical Endocrinology and Metabolism 2009; 94 (4): 1427-1435.

Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, Wohlgemuth S, Hormannsperger G, Loh G, Blaut M, Collie-Duguid E, Haller D, Kelly D. Balancing Inflammatory, Lipid, and Xenobiotic Signaling Pathways by VSL#3, a Biotherapeutic Agent, in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2009; 15 (11): 1721-1736.

Mulder IE, Schmidt B, Stokes CR, Lewis M, Bailey M, Aminov RI, Prosser JI, Gill BP, Pluske JR, Mayer CD, Musk CC, Kelly D. Environmentally-acquired bacteria influence microbial diversity and natural innate immune responses at gut surfaces. BMC Biol. 2009; 7: 79.

Petty RD, Samuel LM, Murray GI, MacDonald G, O’Kelly T, Loudon M, Binnie N, Aly E McKinley AJ, Wang W, Gilbert F, Semple S, Collie-Duguid ESR. APRIL is a novel clinical chemoresistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer, 2009, 9: 434.

Smith TAD, Sharma RI, Wang WG, Welch AE, Schweiger LF, Collie-Duguid ESR. Decreased [18F] fluoro-2-deoxy-D-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro. Nuclear Medicine and Biology 2007; 34: 955-960.

Wang W, McLeod HL , Cassidy J and Collie-Duguid ESR. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemotherapy and Pharmacology 2007; 59: 839-845.

Haughton EL, Tucker SJ, Marek CJ, Durward E, Leel V, Bascal Z, Monaghan T, Koruth M, Collie-Duguid E, Mann DA, Trim JE and Wright MC. Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 2006; 131 (1): 194-209.

Petty RD, Kerr KM, Murray GI, Nicolson MC, Rooney PH, Bissett D, Collie-Duguid ESR. Tumour transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small cell lung cancer. J. Clin. Oncol., 2006, 24, 1729-1744.

Projects

The Aberdeen Microarray Facility has been involved in a diverse range of projects since its inception. These include projects in immunology, malaria, cancer research, fertility, microbiology, agriculture and many more. A brief outline of some Facility projects is provided below to demonstrate the versatility and applicability of this technology.

  • Biomarker and novel drug target discovery in cancer patients and cancer cell line models - colorectal (bowel), lung, oesophageal (gullet), gastric (stomach) and breast cancer
  • Biotherapeutics for inflammatory bowel disease using mammalian models
  • Early life and environmental microbiota and gut immunity using mammalian models
  • Human ovarian reserve and fertility in human samples
  • Drug resistance using cell line models
  • Stem cell differentiation and function - hepatic (liver), mesenchymal and progeny (bone, cartilage), muscle, embryonic, in response to parasites
  • Macrophage function using human blood
  • Toxicology and transporters - in mammals, cell lines and human liver
  • Sepsis in mammalian models
  • Electrophysiology and cell migration
  • Neurotransmitters and synaptic function
  • Osteoarthritis and Osteoporosis in cartilage and bone
  • Molecular mechanisms of resistance to the malarial parasite Plasmodium falciparum in mosquitoes (Anopheles gambiae)
  • Parasitic resistance in rice